acetylleucyl-leucyl-norleucinal has been researched along with phosphotyrosine in 1 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (phosphotyrosine) | Trials (phosphotyrosine) | Recent Studies (post-2010) (phosphotyrosine) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 6,475 | 4 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia, FU; Hu, Y; Stearns, ME; Wang, M | 1 |
1 other study(ies) available for acetylleucyl-leucyl-norleucinal and phosphotyrosine
| Article | Year |
|---|---|
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
Topics: Antibodies; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Humans; Interleukin-10; Leupeptins; Male; Phosphorylation; Phosphotyrosine; Prostatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-rel; Signal Transduction; Staurosporine; Tissue Inhibitor of Metalloproteinase-1 | 2003 |